Immune evasion and provocation by Mycobacterium tuberculosis

P Chandra, SJ Grigsby, JA Philips - Nature Reviews Microbiology, 2022 - nature.com
Mycobacterium tuberculosis, the causative agent of tuberculosis, has infected humans for
millennia. M. tuberculosis is well adapted to establish infection, persist in the face of the host …

The use of RNA-based treatments in the field of cancer immunotherapy

M Chehelgerdi, M Chehelgerdi - Molecular Cancer, 2023 - Springer
Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

Immune cell interactions in tuberculosis

JAL Flynn, J Chan - Cell, 2022 - cell.com
Despite having been identified as the organism that causes tuberculosis in 1882,
Mycobacterium tuberculosis has managed to still evade our understanding of the protective …

Pathogenicity and virulence of Mycobacterium tuberculosis

KC Rahlwes, BRS Dias, PC Campos… - Virulence, 2023 - Taylor & Francis
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Airway T cells are a correlate of iv Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques

PA Darrah, JJ Zeppa, C Wang, EB Irvine, AN Bucsan… - Cell Host & Microbe, 2023 - cell.com
Summary Bacille Calmette-Guerin (BCG), the only approved Mycobacterium tuberculosis
(Mtb) vaccine, provides limited durable protection when administered intradermally …

Intravenous Bacille Calmette–Guérin vaccination protects simian immunodeficiency virus-infected macaques from tuberculosis

EC Larson, AL Ellis-Connell, MA Rodgers… - Nature …, 2023 - nature.com
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the most common cause of
death in people living with human immunodeficiency virus (HIV). Intra-dermal Bacille …

Key advances in vaccine development for tuberculosis—Success and challenges

R Lai, AF Ogunsola, T Rakib, SM Behar - NPJ vaccines, 2023 - nature.com
Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences

A Aiello, S Najafi-Fard, D Goletti - Frontiers in Immunology, 2023 - frontiersin.org
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) and Coronavirus disease-
2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus …

Clinical manifestations and immune response to tuberculosis

ML Carabalí-Isajar, OH Rodríguez-Bejarano… - World Journal of …, 2023 - Springer
Tuberculosis is a far-reaching, high-impact disease. It is among the top ten causes of death
worldwide caused by a single infectious agent; 1.6 million tuberculosis-related deaths were …

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis

SE Larsen, JH Erasmus, VA Reese, T Pecor, J Archer… - Vaccines, 2023 - mdpi.com
Mycobacterium tuberculosis (M. tb), a bacterial pathogen that causes tuberculosis disease
(TB), exerts an extensive burden on global health. The complex nature of M. tb, coupled with …